Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4075-4083

  Riesterer, Oliver ^a   Milas, Luka ^a   Ang, K Kian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMORAZOLE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TEMOZOLOMIDE; TIRAPAZAMINE; TRASTUZUMAB; VATALANIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CLINICAL TRIAL; DRUG MECHANISM; EPSTEIN BARR VIRUS; GLIOBLASTOMA; HEAD AND NECK CANCER; HORMONAL THERAPY; HUMAN; HYPOXIA; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIOSENSITIZATION; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34748856245     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.8497     Document Type: Review

References (74)

1. Steel GG: Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 5:1145-1150, 1979
2. Hall E: Radiobiology for the Radiobiologist (ed 6). Baltimore, MD, Lippincott Williams & Wilkins, 2006
3. Koch W, Sidransky D: Molecular markers of radiation effectiveness in head and neck squamous cell carcinoma. Semin Radiat Oncol 14:130-138, 2004
4. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
5. Gatenby RA, Kessler HB, Rosenblum JS, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
6. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26:45-50, 1993
7. Knocke TH, Weitmann HD, Feldmann HJ, et al: Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 53:99-104, 1999
8. Nordsmark M, Overgaard J: A confirmatory prognostic study on oxygenation status and locoregional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 57:39-43, 2000
9. Aebersold DM, Burri P, Beer KT, et al: Expression of hypoxia-inducible factor-1 alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911-2916, 2001
10. Bachtiary B, Schindl M, Potter R, et al: Overexpression of hypoxia-inducible factor-1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 9:2234-2240, 2003
11. Burri P, Djonov V, Aebersold DM, et al: Significant correlation of hypoxia-inducible factor-1 alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 56:494-501, 2003
12. Koukourakis Ml, Giatromanolaki A, Sivridis E, et al: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202, 2002
13. Loncaster JA, Harris AL, Davidson SE, et al: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: Correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61:6394-6399, 2001
14. Kaanders JH, Wijffels Kl, Marres HA, et al: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066-7074, 2002
15. Le QT, Sutphin PD, Raychaudhuri S, et al: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67, 2003
16. Overgaard J, Eriksen JG, Nordsmark M, et al: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764, 2005
17. Rischin D, Hicks RJ, Fisher R, et al: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098-2104, 2006
18. Koukourakis Ml, Bentzen SM, Giatromanolaki A, et al: Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735, 2006
19. Wang GL, Semenza GL: General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 90:4304-4308, 1993
20. Bentzen SM: Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 6:112-117, 2005
21. Chao KS, Bosch WR, Mutic S, et al: A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49:1171-1182, 2001
22. Grandis J, Tweardy D: Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579-3584, 1993
23. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002
24. Psyrri A, Yu Z, Weinberger PM, et al: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11:5856-5862, 2005
25. Chua DTT, Nicholls JM, Sham JST, et al: Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59:11-20, 2004
26. Bentzen SM, Atasoy BM, Daley FM, et al: Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23:5560-5567, 2005
27. Eriksen JG, Steiniche T, Askaa J, et al: The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58:561-566, 2004
28. Lo YM, Chan LY, Lo KW, et al: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59:1188-1191, 1999
29. Chan ATC, Lo YMD, Zee B, et al: Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94:1614-1619, 2002
30. Lin JC, Wang WY, Chen KY, et al: Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350:2461-2470, 2004
31. McGuire WL: The usefulness of steroid hormone receptors in the management of primary and advanced breast cancer. Eur J Cancer 1:39-43, 1980 (suppl)
32. Fisher B, Bryant J, Dignam JJ, et al: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141-4149, 2002
33. Paulsen GH, Stricken T, Marthinsen AB, et al: Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol 35:1011-1019, 1996
34. Wazer DE, Tercilla OF, Lin PS, et al: Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br J Radiol 62:1079-1083, 1989
35. Sarkaria JN, Miller EM, Parker CJ, et al: 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res Treat 30:159-165, 1994
36. Ahn PH, Vu HT, Lannin D, et al: Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23:17-23, 2005
37. Harris EE, Christensen VJ, Hwang WT, et al: Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23:11-16, 2005
38. Pierce LJ, Hutchins LF, Green SR, et al: Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23:24-29, 2005
39. Liang K, Lu Y, Jin W, et al: Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2:1113-1120, 2003
40. Wright C, Mellon K, Neal DE, etal: Expression of c-erbB-2 protein product in bladder cancer. Br J Cancer 62:764-765, 1990
41. Kattan MW, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21:4568-4571, 2003
42. Kattan MW, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352-3359, 2000
43. Small EJ, Roach M III: Prostate-specific antigen in prostate cancer: A case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol 29:264-273, 2002
44. Hanks GE, Hanlon AL, Pinover WH, et al: Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46:823-832, 2000
45. Pollack A, Zagars GK, Smith LG, et al: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911, 2000
46. Symon Z, Griffith KA, McLaughlin PW, et al: Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 57:384-390, 2003
47. Catton C, Gospodarowicz M, Warde P, et al: Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 59:51-60, 2001
48. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19:1030-1039, 2001
49. Denham JW, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005
50. Pollack A, Ashoori F, Sikes C, et al: The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys 46:153-158, 2000
51. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
52. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
53. Nabell L, Spencer S: Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 30:89-93, 2003
54. O'Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300, 1997
55. Apisarnthanarax S, Alauddin MM, Mourtada F, et al: Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H- fluorothymidine using preclinical tumor models. Clin Cancer Res 12:4590-4597, 2006
56. Begg AC: Cisplatin and radiation: Interaction probabilities and therapeutic possibilities. Int J Radiat Oncol Biol Phys 19:1183-1189, 1990
57. Dewit L: Combined treatment of radiation and cisdiamminedichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403-426, 1987
58. Wilson GD, Bentzen SM, Harari PM: Biologic basis for combining drugs with radiation. Semin Radiat Oncol 16:2-9, 2006
59. Dolling JA, Boreham DR, Brown DL, et al: Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae. Mutat Res 433:127-136, 1999
60. Myint WK, Ng C, Raaphorst GP: Examining the non-homologous repair process following cisplatin and radiation treatments. Int J Radiat Biol 78:417-424, 2002
61. Brown JM, Lemmon MJ: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50:7745-7749, 1990
62. Dorie MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993
63. Rischin D, Peters L, Hicks R, etal: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19:535-542, 2001
64. Mauceri HJ, Hanna NN, Beckett MA, et al: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291, 1998
65. Geng L, Donnelly E, McMahon G, et al: Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413-2419, 2001
66. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004
67. Tong RT, Boucher Y, Kozin SV, et al: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004
68. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
69. Riesterer O, Honer M, Jochum W, et al: Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment. Clin Cancer Res 12:3518-3524, 2006
70. Jain RK, Duda DG, Clark JW, et al: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40, 2006
71. Komaki R, Liao Z, Milas L: Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 31:47-53, 2004
72. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
73. Sequist LV, Bell DW, Lynch TJ, et al: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595, 2007
74. Das AK, Satom M, Story MD, et al: Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 66:9601-9608, 2006